NanoVax Herpes Simplex Virus Vaccine Description 2022
NanoVax is an adjuvant platform used in the development of a vaccine candidate that will provide protection against the two viruses that can cause genital herpes. The subunit vaccine composition comprises isolated surface glycoproteins from herpes simplex viruses, fusion proteins, or fragments mixed in varied combinations with a nanoemulsion, which is a potent immune enhancer.
NanoVax Indication
This vaccine candidate will provide protection against HSV1 and HSV2, two viruses that cause genital herpes.
NanoVax Dosage
NanoVax is administered intranasally.
Intranasal NanoVax platform elicits both mucosal and systemic immunity through its novel oil-in-water nanoemulsion (NE) adjuvant, offering a unique advantage to combat sexually transmitted infections (STIs) including genital herpes.
The mucosal immunity elicited by intranasal NE vaccines provides critical protection against infections at the port of entry by which a pathogen enters the body.
The intranasal NanoVax HSV vaccine has demonstrated safety and efficacy in both prophylactic and therapeutic animal models for genital herpes.
In a prophylactic guinea pig study, the intranasal vaccine prevented genital herpes infection in 92 percent of animals vaccinated.
Therapeutic study animals previously infected with genital herpes who received the BlueWillow NanoVax vaccine reduced recurrent lesions and viral shedding by more than 50 percent compared to animals who received no treatment.
NanoVax News 2018 - 2022
September 21, 2021 - Announced the formation of the Company’s Scientific Advisory Board (SAB) with three leading viral infectious disease experts. The SAB will provide strategic and scientific counsel to BlueWillow’s clinical programs. Robin Isaacs, M.D., Akiko Iwasaki, Ph.D. and Steve Projan, Ph.D. are newly named members of the SAB.
July 23, 2019 - Announced the issuance of U.S. patent number 10,206,996 to BlueWillow for the development of an intranasal NanoVax® herpes simplex virus (HSV) vaccine. The patent protects the use of BlueWillow’s unique NanoVax adjuvant platform in the development of a vaccine that provides protection against HSV-1 and HSV-2, the two viruses that can cause genital herpes.
May 7, 2018 - NanoBio Corporation, a clinical-stage biopharmaceutical company, announced that it has changed its corporate name to BlueWillow Biologics® in conjunction with the closing of a $10 million Series A financing. The Series A financing round was led by North Coast Technology Investors, Line Moon Ventures and the University of Michigan through its MINTS initiative.
Recent research conducted by the University of Cincinnati in conjunction with BlueWillow has demonstrated that an intranasal NE vaccine elicits protection in both the prophylactic & therapeutic guinea pig models for HSV-2.